We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Sponsor content
356 result(s) found, displaying 11 to 20
-
Jan-2026Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Dec-2025Prescription medicine evaluationActive ingredient: Pneumococcal purified capsular polysaccharides.
-
Oct-2025Prescription medicine evaluationActive ingredient: pembrolizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WELIREG belzutifan 40 mg film-coated tablet blister pack.
-
Australian public assessment report (AusPar)Capvaxive is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) in adults 18 years of age and older.
-
Australian public assessment report (AusPar)Winrevair (sotatercept) has been approved for the treatment of adults with pulmonary arterial hypertension (PAH) in WHO Functional Class (FC) II or III, in combination with standard therapy.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CAPVAXIVE Pneumococcal 21-valent Conjugate Vaccine 0.5 mL Solution for Injection Pre-filled Syringe.
-
Prescription medicine registrationActive ingredients: pembrolizumab.
-
Prescription medicine registrationActive ingredients: pembrolizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Merck Sharp & Dohme (Australia) Pty Ltd - Prefilled syringe/needle.